Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Infantile-onset Pompe disease (IOPD) is a rare inherited neuromuscular disorder caused by acid alpha-glucosidase deficiency, leading to glycogen accumulation in muscles. As per Weijing Kong et al. (2024), the global birth prevalence of IOPD was 1 per 100,000 live births. According to the infantile-onset Pompe disease (IOPD) epidemiology forecast by Expert Market Research, epidemiological trends remain important for understanding the disease burden, patient population, and evolving patterns of diagnosis across the eight major markets.
Base Year
Historical Period
Forecast Period

Read more about this report - Request a Free Sample
Expert Market Research's “Infantile-Onset Pompe Disease (IOPD) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of infantile-onset Pompe disease (IOPD). It projects the future incidence and prevalence rates of infantile-onset Pompe disease (IOPD) cases across various populations. The study covers age, gender, and type as major determinants of the infantile-onset Pompe disease (IOPD) population. The report highlights patterns in the prevalence of infantile-onset Pompe disease (IOPD) over time and projects future trends based on multiple variables.
The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of infantile-onset pompe disease (IOPD) in the 8 major markets.
Regions Covered
Infantile-onset Pompe disease (IOPD) is a rare, autosomal recessive lysosomal storage disorder caused by pathogenic variants in the GAA gene, resulting in deficient acid alpha-glucosidase (GAA) activity and progressive glycogen accumulation, particularly in cardiac and skeletal muscle. Classic IOPD typically presents within the first year of life with generalized hypotonia, muscle weakness, feeding difficulties, respiratory impairment, and hypertrophic cardiomyopathy. Pompe disease is broadly classified into infantile-onset and late-onset forms, with IOPD representing the more rapidly progressive phenotype. GAA enzyme deficiency is the underlying biochemical abnormality.
|
Parameter |
Insight |
|
Largest Patient Pool |
United States |
|
Fastest Growing Country |
India |
|
High-Risk Population |
Newborns with biallelic pathogenic GAA variants, particularly infants with severe GAA deficiency and CRIM-negative status. |
|
Key Diagnostic Method |
Newborn screening using dried blood spots for GAA enzyme activity, followed by confirmatory enzyme and molecular genetic testing. |
|
Major Risk Factor |
Pathogenic variants in the GAA gene inherited in an autosomal recessive pattern. |
|
Major gap in the market |
Delayed or incomplete diagnosis and uneven access to newborn screening, particularly where systematic screening and confirmatory testing are less established. |
The infantile-onset Pompe disease (IOPD) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the infantile-onset Pompe disease (IOPD) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for infantile-onset Pompe disease (IOPD) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
|
Epidemiology Segment |
Key Insights |
|
Diagnosed Prevalent Cases of the Disease |
According to Weijing Kong et al. (2024), the global birth prevalence of infantile-onset Pompe disease was 1.0 case per 100,000 live births (95% CI: 0.5–1.5). According to Sanofi, IOPD prevalence is approximately 1 in 138,000 people. |
|
Gender-Specific Cases of the Disease |
Epidemiological assessment of IOPD encompasses both male and female populations, with disease occurrence primarily evaluated through birth-screening and diagnostic programs. The available epidemiological findings emphasize geographic and population-level differences rather than sex-specific variation. |
|
Age-Specific Cases of the Disease |
IOPD is characterized by disease presentation during infancy. Classic IOPD can present during the first days of life, while non-classic IOPD generally presents during the first year, establishing infancy as the principal age group for disease identification. |
|
Ethnicity-Wise Cases of the Disease |
According to Roberto Giugliani et al. (2025), epidemiological estimates vary according to geographic and ethnic populations. Studies have reported higher prevalence among populations of African descent, while pseudodeficiency alleles occur more frequently in some Asian populations. |
|
Mortality and Survival Analysis of the Disease |
IOPD has a substantial early-life disease burden, particularly in classic presentations. Untreated classic IOPD may result in death during the first year because of hypertrophic cardiomyopathy, while non-classic disease generally follows a slower progression. |
|
Disease Type |
Prevalence |
|
Classic IOPD |
Classic IOPD represents the severe infantile presentation, with onset during the first days of life and rapid disease progression characterized by cardiomyopathy, muscle weakness, and respiratory involvement. |
|
Non-classic IOPD |
Non-classic IOPD generally presents during the first year of life and follows a slower progression than classic IOPD, although progressive muscle weakness and respiratory complications contribute to disease burden. |

Read more about this report - Request a Free Sample
The infantile-onset Pompe disease (IOPD) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.
|
Country |
Key Insights |
|
United States |
According to the Muscular Dystrophy Association, Pompe disease occurs in approximately 1 in 22,000 live births in the United States. The United States therefore represents an important population for epidemiological assessment through newborn screening, diagnostic testing, and identification of infantile presentations. |
|
Germany |
Germany contributes to the European epidemiological landscape of Pompe disease, where prevalence estimates vary across populations and diagnostic approaches. European studies constitute a substantial component of the available epidemiological evidence, supporting continued assessment of birth prevalence and early diagnosis of IOPD. |
|
France |
According to Roberto Giugliani et al. (2025), the French National Pompe Registry included 246 individuals and demonstrated increasing diagnosis of late-onset Pompe disease over successive periods. The French epidemiological landscape also reflects the importance of registry-based identification and longitudinal disease surveillance. |
|
Italy |
Italy forms part of the European newborn-screening landscape for Pompe disease. Epidemiological assessment in the country is associated with newborn screening and identification of affected infants, supporting earlier recognition of IOPD within the pediatric population. |
|
Spain |
Spain represents part of the European epidemiological context for Pompe disease, where population-based diagnosis and newborn screening contribute to identifying affected infants. The broader European evidence demonstrates geographic variation in Pompe disease birth prevalence. |
|
United Kingdom |
According to Jordi Díaz-Manera et al. (2025), Pompe disease prevalence in the United Kingdom is approximately 1 in 40,000, while the worldwide incidence of IOPD is approximately 1 in 138,000. The source estimates 35–40 children living with IOPD in the United Kingdom. |
|
Japan |
As per Roberto Giugliani et al. (2025), newborn-screening studies estimated IOPD birth prevalence at approximately 1 in 297,387 in Japan. This finding illustrates geographic variation in IOPD prevalence and highlights the contribution of newborn screening to identifying affected infants. |
|
India |
India represents a large pediatric population in which recognition of rare inherited disorders such as IOPD depends on early clinical identification, biochemical assessment, and genetic confirmation. Epidemiological assessment is particularly relevant to improving recognition of affected infants and understanding population-level disease burden. |
A major epidemiological gap in IOPD is the inconsistent availability and implementation of newborn screening across countries, which can delay diagnosis and treatment during a period when disease progression may be rapid. Expanding standardized newborn screening, particularly in India, could improve early case identification and facilitate timely confirmatory testing and treatment. Another opportunity involves strengthening molecular testing and CRIM-status assessment following abnormal screening results. Across the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India, greater harmonization of diagnostic pathways and longitudinal epidemiological registries could improve estimates of disease burden and treatment needs.
Infantile-onset Pompe disease treatment requires early initiation of disease-specific therapy to limit irreversible muscle and cardiac damage. Enzyme replacement therapy (ERT) with recombinant human acid alpha-glucosidase is the principal targeted treatment and should generally begin promptly after diagnosis. Before ERT, cross-reactive immunologic material (CRIM) status is assessed because CRIM-negative infants are at increased risk of developing high-titer antibodies against the replacement enzyme. Immunomodulatory therapy may therefore be administered alongside ERT to promote immune tolerance. Multidisciplinary supportive care, including respiratory, nutritional, cardiac, physical, and developmental management, is also important.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Report Features |
Details |
|
Base Year |
2025 |
|
Historical Period |
2019-2025 |
|
Forecast Period |
2026-2035 |
|
Epidemiology Statistics Provided |
|
|
Segmentation Provided |
|
|
Geographies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.